Biotech | December 17, 2021
New data suggests Covaxin generates robust memory to Covid-19 and variants six months after vaccination
Effectiveness of Covaxin against the Omicron variant is currently being studied
Effectiveness of Covaxin against the Omicron variant is currently being studied
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Subscribe To Our Newsletter & Stay Updated
